Therefore, the molecular targeting of the EGFR by monoclonal antibodies, such as cetuximab, is a Food and Drug Administration (FDA)-approved therapeutic strategy for HNSCC patients [7]. Here, EGFR is linked to head and neck squamous cell carcinoma.